TOPLINE:
Dolutegravir plus lamivudine demonstrates noninferiority to the standard-of-care three-drug regimen in treatment-naive patients with HIV without preliminary drug resistance testing.
METHODOLOGY:
- Researchers conducted a randomized, noninferiority, phase 4 trial to evaluate the efficacy and safety of dolutegravir plus lamivudine in untreated patients with HIV with no preliminary drug resistance testing.
- Overall, 223 participants (median age, 31 years; 77% men) were enrolled, of whom 106 received the two-drug regimen of dolutegravir plus lamivudine and 108 received the three-drug regimen of dolutegravir plus tenofovir disoproxil fumarate with either emtricitabine or lamivudine.
- Drug resistance testing was performed at the start of the treatment and was kept double-blinded…